

Please type a plus sign (+) inside this box → **[+]**

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/648,569
		Filing Date	August 25, 2000
		First Named Inventor	Anders, Hjelholt Pederson
		Group Art Unit	1633
		Examiner Name	Unassigned
Total Number of Pages in This Submission	6	Attorney Docket Number	31-107600US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <input type="checkbox"/> 40 references, receipt acknowledgment postcard
<input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)		
<input type="checkbox"/> Extension of Time Request		
<input type="checkbox"/> Express Abandonment Request		
<input checked="" type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Gwynedd Warren, Reg. No. 45,200 The Law Offices of Jonathan Alan Quine
Signature	
Date	June 25, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: June 25, 2001

Typed or printed name	Alexandra Allison
Signature	
Date	June 25, 2001

I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231,
On June 25, 2001

The Law Offices of Jonathan Alan Quine
By Alexandra Allison
Alexandra Allison

Attorney Docket No. 31-107600US
Client Ref. No. 2us2, LAR/KH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Anders, Hjelholt Pedersen, *et al.*

Application No.: 09/648,569

Filed: August 25, 2000

For: NEW INTERFERON β -LIKE
MOLECULES

Examiner: Unassigned

Art Unit: 1633

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Assistant Commissioner for Patents
Washington , D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Gwynedd Warren
Reg. No. 45,200

THE LAW OFFICES OF JONATHAN ALAN QUINE
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871
Fax: (510) 337-7877

GW:afa

TO THE U.S. PATENT & TRADEMARK OFFICE
Please stamp the date of receipt of the following document(s) and return this card to us

RE: Information Disclosure Statement for NEW INTERFERON β-LIKE MOLECULES

TITLE OF DOCUMENT(S):

- Information Disclosure Statement
- PTO-form 1449
- Cited References (40)
- Transmittal Sheet

Application No. 09/648,569
File No. 31-107600US
Date Mailed June 25, 2001
Atty/Secty. GW:afa



JUL 05 2001

LAW OFFICES OF
JONATHAN ALAN QUINE